Preoperative Dexamethasone to Improve Quality of Recovery After Laparoscopic Bariatric Surgery

Sponsor
Ondokuz Mayıs University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05752734
Collaborator
(none)
60
1
3.9
15.3

Study Details

Study Description

Brief Summary

In the obese patient, adequate pain relief in the postoperative period is an important parameter that affects patient comfort and hospital stay. Increasing patient comfort and recovery quality can be achieved by avoiding undesirable effects such as nausea and vomiting, as well as analgesia. In our study, our aim is to evaluate the effect of dexamethasone added to multimodal analgesia on postoperative patient comfort in the obese patient group with a 40-item scale.

Condition or Disease Intervention/Treatment Phase
  • Procedure: dexamethasone group
  • Procedure: control group

Detailed Description

Postoperative pain prolongs hospital stay, delays wound healing, increases infection rates, and increases the incidence of drug side effects due to the use of systemic pain relievers (especially opioids).

Good pain control facilitates respiratory effort, allows the patient to perform respiratory exercises and cough to correct the increased thoracic fat mass and impaired respiratory mechanics due to anesthesia. The patient without pain is mobilized early and discharged early.

Our aim is to evaluate the effect of dexamethasone added to multimodal analgesia on postoperative patient comfort in the obese patient group with a 40-item scale.

Patients will be divided in to two groups (group D and group C):
Group D (Dexamethasone Group):

Patients who used/applied dexamethasone before bariatric surgery were included in this group.

Group C(Control Group):

Patients who did not use dexamethasone or steroid-derived drugs were included in this group.

The patients included in the study were evaluated with the 40-item recovery quality scale (QoR-40) 24 hours after the operation.

İn addition all patients will be administered iv morphine pca (patient controlled analgesia) for the first 24 hours postoperatively

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Preoperative Dexamethasone Enhances Quality of Recovery After Laparoscopic Bariatric Surgery: A Prospective Observational Study
Actual Study Start Date :
Feb 2, 2023
Anticipated Primary Completion Date :
Mar 25, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Group D

Patients who used/applied dexamethasone before bariatric surgery were included in this group.

Procedure: dexamethasone group
Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group. Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation.

Group C

Patients who did not use dexamethasone or steroid-derived drugs were included in this group.

Procedure: control group
Patients not administered dexamethasone will be included in this group. Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation.

Outcome Measures

Primary Outcome Measures

  1. Global Quality of Recovery (QoR-40) score in the first 24 hours after surgery [postoperative day 1]

    The recovery quality of the patients 24 hours after the operation will be evaluated with the QoR-40 questionnaire. The questionnaire consists of 40 questions that examine five domains of patient recovery using a five point Likert scale: none of the time, some of the time, usually, most of the time, and all of the time. The five domains include physical comfort, pain, physical independence, psychological support, and emotional state. As a result of the evaluation, the total score ranges from 40 (worst review quality score) to 200 (best review quality score).

  2. The score for each of the five parameters that make up the QoR-40 questionnaire [postoperative day 1]

    It consists of 5 parameters: physical independence score (n = 5), patient support score (n = 7), Physical comfort score (n = 12), emotional state score (n = 9) and pain score (n = 7).

Secondary Outcome Measures

  1. Morphine consumption in the first 24 hours after surgery [postoperative day 1]

    Morphine consumption in the first 24 hours will be measured. Patients will be able to request opioids via a PCA device when their NRS score ≥3.

  2. The incidences of post-operative nausea and vomiting (PONV) [postoperative day 1]

    Post-operative nausea and vomiting (PONV) will be evaluated with a verbal descriptive scale. (0 = None at all, 1 = Mild nausea, 2 = Moderate nausea, 3 = Vomiting once, 4 = Vomiting more than once)

  3. Time to first mobilization [Up to 24 hours after surgery.]

    The patients first mobilization time after the operation will be recorded.

  4. Time to discharge [Trough hospital stay, an average of 1 week]

    The length of hospital stay will be recorded.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Body mass index>30 kg/m2

  • The American Society of Anaesthesiologists (ASA) physical status class I II

  • Patients who will undergo an elective laparoscopic sleeve gastrectomy (LSG)

  • Those who are literate enough to answer the compilation quality score (QoR-40) questionnaire

Exclusion Criteria:
  • refusal to participate

  • allergy to the study drugs

  • chronic kidney disease (creatinine>150 μmol/L)

  • mental illness

  • liver, respiratory or oncological disease,

  • cardiac dysfunction (ejection fraction <40%),

  • uncontrolled hypertension,

  • preoperative analgesic use,

  • chronic pain,

  • history of alcohol or drug addiction

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ondokuzmayıs University Samsun Turkey 55060

Sponsors and Collaborators

  • Ondokuz Mayıs University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yasemin Burcu Ustun, Professor, Ondokuz Mayıs University
ClinicalTrials.gov Identifier:
NCT05752734
Other Study ID Numbers:
  • SLGQR402022
First Posted:
Mar 3, 2023
Last Update Posted:
Mar 3, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yasemin Burcu Ustun, Professor, Ondokuz Mayıs University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 3, 2023